An Overview Of Pre License Inspections For Biotech Products 515 Global Quality

Summary

Zhihao Peter Qiu, CDER Office of Pharmaceutical A data-driven look at how manufacturers and sponsors can prepare for Mahesh Ramanadham and Derek Smith, CDER Office of Pharmaceutical B.J. Ryan, CDER Office of Pharmaceutical Have you considered the consequence for your approved, or in development, biosimilars The FDA Group's CEO, Nick Capman, sits down with Former FDA Investigator, Christopher Smith to dive deep into FDA ... FDA discusses the purposes, conduct, and expectations of FDA drug manufacturing Steven Niedelman offers advice on how to prepare for an FDA Have a question for the speakers or panelists? Email your questions to OTPEvents The FDA's Center for Biologics ... Sean Marcsisin from the FDA Office of Regulatory Affairs explains the This Expert Insights webinar presented by MMS Holdings will provide an informational FDA's Office of Regulatory Affairs' Lucila B. Nwatu describes the general inspectional approach for FDA